HbA1c as a risk factor for heart failure in persons with diabetes

The Atherosclerosis Risk in Communities (ARIC) study

A. Pazin-Filho, A. Kottgen, A. G. Bertoni, S. D. Russell, Elizabeth Selvin, W. D. Rosamond, Josef Coresh

Research output: Contribution to journalArticle

Abstract

Aims/hypothesis: Heart failure (HF) incidence in diabetes in both the presence and absence of CHD is rising. Prospective population-based studies can help describe the relationship between HbA1c, a measure of glycaemia control, and HF risk. Methods: We studied the incidence of HF hospitalisation or death among 1,827 participants in the Atherosclerosis Risk in Communities (ARIC) study with diabetes and no evidence of HF at baseline. Cox proportional hazard models included age, sex, race, education, health insurance status, alcohol consumption, BMI and WHR, and major CHD risk factors (BP level and medications, LDL- and HDL-cholesterol levels, and smoking). Results: In this population of persons with diabetes, crude HF incidence rates per 1,000 person-years were lower in the absence of CHD (incidence rate 15.5 for CHD-negative vs 56.4 for CHD-positive, p1c was 1.17 (95% CI 1.11-1.25) for the non-CHD group and 1.20 (95% CI 1.04-1.40) for the CHD group. When the analysis was limited to HF cases which occurred in the absence of prevalent or incident CHD (during follow-up) the adjusted HR remained 1.20 (95% CI 1.11-1.29). Conclusions/interpretations: These data suggest HbA1c is an independent risk factor for incident HF in persons with diabetes with and without CHD. Long-term clinical trials of tight glycaemic control should quantify the impact of different treatment regimens on HF risk reduction.

Original languageEnglish (US)
Pages (from-to)2197-2204
Number of pages8
JournalDiabetologia
Volume51
Issue number12
DOIs
StatePublished - Dec 2008

Fingerprint

Atherosclerosis
Heart Failure
Incidence
Insurance Coverage
Sex Education
Risk Reduction Behavior
Health Insurance
Proportional Hazards Models
Alcohol Drinking
LDL Cholesterol
HDL Cholesterol
Population
Health Status
Hospitalization
Smoking
Clinical Trials

Keywords

  • Diabetes
  • HbA
  • Heart failure

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

HbA1c as a risk factor for heart failure in persons with diabetes : The Atherosclerosis Risk in Communities (ARIC) study. / Pazin-Filho, A.; Kottgen, A.; Bertoni, A. G.; Russell, S. D.; Selvin, Elizabeth; Rosamond, W. D.; Coresh, Josef.

In: Diabetologia, Vol. 51, No. 12, 12.2008, p. 2197-2204.

Research output: Contribution to journalArticle

Pazin-Filho, A. ; Kottgen, A. ; Bertoni, A. G. ; Russell, S. D. ; Selvin, Elizabeth ; Rosamond, W. D. ; Coresh, Josef. / HbA1c as a risk factor for heart failure in persons with diabetes : The Atherosclerosis Risk in Communities (ARIC) study. In: Diabetologia. 2008 ; Vol. 51, No. 12. pp. 2197-2204.
@article{2540be692e7f450485522facc327fc8b,
title = "HbA1c as a risk factor for heart failure in persons with diabetes: The Atherosclerosis Risk in Communities (ARIC) study",
abstract = "Aims/hypothesis: Heart failure (HF) incidence in diabetes in both the presence and absence of CHD is rising. Prospective population-based studies can help describe the relationship between HbA1c, a measure of glycaemia control, and HF risk. Methods: We studied the incidence of HF hospitalisation or death among 1,827 participants in the Atherosclerosis Risk in Communities (ARIC) study with diabetes and no evidence of HF at baseline. Cox proportional hazard models included age, sex, race, education, health insurance status, alcohol consumption, BMI and WHR, and major CHD risk factors (BP level and medications, LDL- and HDL-cholesterol levels, and smoking). Results: In this population of persons with diabetes, crude HF incidence rates per 1,000 person-years were lower in the absence of CHD (incidence rate 15.5 for CHD-negative vs 56.4 for CHD-positive, p1c was 1.17 (95{\%} CI 1.11-1.25) for the non-CHD group and 1.20 (95{\%} CI 1.04-1.40) for the CHD group. When the analysis was limited to HF cases which occurred in the absence of prevalent or incident CHD (during follow-up) the adjusted HR remained 1.20 (95{\%} CI 1.11-1.29). Conclusions/interpretations: These data suggest HbA1c is an independent risk factor for incident HF in persons with diabetes with and without CHD. Long-term clinical trials of tight glycaemic control should quantify the impact of different treatment regimens on HF risk reduction.",
keywords = "Diabetes, HbA, Heart failure",
author = "A. Pazin-Filho and A. Kottgen and Bertoni, {A. G.} and Russell, {S. D.} and Elizabeth Selvin and Rosamond, {W. D.} and Josef Coresh",
year = "2008",
month = "12",
doi = "10.1007/s00125-008-1164-z",
language = "English (US)",
volume = "51",
pages = "2197--2204",
journal = "Diabetologia",
issn = "0012-186X",
publisher = "Springer Verlag",
number = "12",

}

TY - JOUR

T1 - HbA1c as a risk factor for heart failure in persons with diabetes

T2 - The Atherosclerosis Risk in Communities (ARIC) study

AU - Pazin-Filho, A.

AU - Kottgen, A.

AU - Bertoni, A. G.

AU - Russell, S. D.

AU - Selvin, Elizabeth

AU - Rosamond, W. D.

AU - Coresh, Josef

PY - 2008/12

Y1 - 2008/12

N2 - Aims/hypothesis: Heart failure (HF) incidence in diabetes in both the presence and absence of CHD is rising. Prospective population-based studies can help describe the relationship between HbA1c, a measure of glycaemia control, and HF risk. Methods: We studied the incidence of HF hospitalisation or death among 1,827 participants in the Atherosclerosis Risk in Communities (ARIC) study with diabetes and no evidence of HF at baseline. Cox proportional hazard models included age, sex, race, education, health insurance status, alcohol consumption, BMI and WHR, and major CHD risk factors (BP level and medications, LDL- and HDL-cholesterol levels, and smoking). Results: In this population of persons with diabetes, crude HF incidence rates per 1,000 person-years were lower in the absence of CHD (incidence rate 15.5 for CHD-negative vs 56.4 for CHD-positive, p1c was 1.17 (95% CI 1.11-1.25) for the non-CHD group and 1.20 (95% CI 1.04-1.40) for the CHD group. When the analysis was limited to HF cases which occurred in the absence of prevalent or incident CHD (during follow-up) the adjusted HR remained 1.20 (95% CI 1.11-1.29). Conclusions/interpretations: These data suggest HbA1c is an independent risk factor for incident HF in persons with diabetes with and without CHD. Long-term clinical trials of tight glycaemic control should quantify the impact of different treatment regimens on HF risk reduction.

AB - Aims/hypothesis: Heart failure (HF) incidence in diabetes in both the presence and absence of CHD is rising. Prospective population-based studies can help describe the relationship between HbA1c, a measure of glycaemia control, and HF risk. Methods: We studied the incidence of HF hospitalisation or death among 1,827 participants in the Atherosclerosis Risk in Communities (ARIC) study with diabetes and no evidence of HF at baseline. Cox proportional hazard models included age, sex, race, education, health insurance status, alcohol consumption, BMI and WHR, and major CHD risk factors (BP level and medications, LDL- and HDL-cholesterol levels, and smoking). Results: In this population of persons with diabetes, crude HF incidence rates per 1,000 person-years were lower in the absence of CHD (incidence rate 15.5 for CHD-negative vs 56.4 for CHD-positive, p1c was 1.17 (95% CI 1.11-1.25) for the non-CHD group and 1.20 (95% CI 1.04-1.40) for the CHD group. When the analysis was limited to HF cases which occurred in the absence of prevalent or incident CHD (during follow-up) the adjusted HR remained 1.20 (95% CI 1.11-1.29). Conclusions/interpretations: These data suggest HbA1c is an independent risk factor for incident HF in persons with diabetes with and without CHD. Long-term clinical trials of tight glycaemic control should quantify the impact of different treatment regimens on HF risk reduction.

KW - Diabetes

KW - HbA

KW - Heart failure

UR - http://www.scopus.com/inward/record.url?scp=55749088028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55749088028&partnerID=8YFLogxK

U2 - 10.1007/s00125-008-1164-z

DO - 10.1007/s00125-008-1164-z

M3 - Article

VL - 51

SP - 2197

EP - 2204

JO - Diabetologia

JF - Diabetologia

SN - 0012-186X

IS - 12

ER -